Treatment of Premature Retinopathy with Biosimilar Ranibizumab Seems Effective.

Published Date: 27 Apr 2023

Treatment of Retinopathy of Prematurity with Biosimilar Ranibizumab Seems Effective.

Read Full News

Latest News

Dry Eye Drug Does Well in Study, but FDA Remains Unconvinced

The drug, reproxalap, led to reductions in symptoms of dry eye, but regulators have repeatedly refused to approve it for this condition.

Sarcoid Uveitis: 1 in 3 Achieve Remission, Relapses Rare

Remission is achievable and relapses are uncommon in patients with sarcoid uveitis, although those with swelling in the macular region may experience delayed remission.

Female Eye Doctors Earn Less Across All Ranks

Women in academic ophthalmology earn less than men across all ranks, with a pay-gap over a full career of roughly $1 million, a study finds.

US FDA Declines to Approve Aldeyra's Eye Disorder Drug, Shares Slump

The U.S. Food and Drug Administration declined to approve Aldeyra Therapeutics' drug for a type ⁠of eye disease, the company said on Tuesday, sending its shares plunging...

Light Therapy May Improve Vision in Patients With Dry AMD

Light therapy with multiple wavelengths may safely improve vision, reduce new retinal damage, and improve vision related quality of life in patients with dry age related macular degeneration.

Spanish Researchers Develop Low-cost Artificial Cornea From Fish Scales

Researchers at Spain's University of Granada have developed an artificial cornea made from the scales ⁠of several fish species commonly found in markets, which could become...

Todays Updates

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Todays Updates

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Latest News

The drug, reproxalap, led to reductions in symptoms of dry eye, but regulators have repeatedly refused to approve it for this condition.

Remission is achievable and relapses are uncommon in patients with sarcoid uveitis, although those with swelling in the macular region may experience delayed remission.

Women in academic ophthalmology earn less than men across all ranks, with a pay-gap over a full career of roughly $1 million, a study finds.

The U.S. Food and Drug Administration declined to approve Aldeyra Therapeutics' drug for a type ⁠of eye disease, the company said on Tuesday, sending its shares plunging...

Light therapy with multiple wavelengths may safely improve vision, reduce new retinal damage, and improve vision related quality of life in patients with dry age related macular degeneration.

Researchers at Spain's University of Granada have developed an artificial cornea made from the scales ⁠of several fish species commonly found in markets, which could become...

News All Time

Metabolic Syndrome Tied to Glaucoma Risk

Metabolic syndrome, rather than BMI or waist circumference, is linked to an increased likelihood of glaucoma and may better identify adults who could benefit from closer eye screening.

Two Biologics Show Comparable Benefit in Uveitis

Adalimumab and tocilizumab perform similarly in controlling inflammation while reducing the use of corticosteroids at week 16 in patients with refractory, noninfectious uveitis.

Ocular Therapeutix Plunges as Modest Benefit Overshadow Trial Win Over Regeneron's Eylea

Ocular Therapeutix's experimental eye drug showed superiority to Regeneron's Eylea in a key late-stage trial, but ⁠its modest advantage and higher rates of certain side...

Early Retinal Fluid Drying May Extend Injection Gaps in AMD

Rapid drying of retinal fluid with faricimab injections may help identify patients with neovascular age-related macular degeneration who can safely extend time between injections.

PDS Ranibizumab Retains Visual Acuity Gains in nAMD, with John Kitchens, MD John W. Kitchens, MD

The ongoing Archway-Portal extension study indicates the lasting efficacy and safety of ranibizumab dosing via the Port Delivery System.

FDA Approves First Dual-Agent Eye Drop for Near Vision Loss

FDA Approves First Dual-Agent Eye Drop for Near Vision Loss

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension

FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension

The HCPFive: Top News for Healthcare Providers from the Week of 12/28

The HCPFive: Top News for Healthcare Providers from the Week of 12/28

FDA Issues Complete Response Letter for ONS-5010 for Wet AMD

FDA Issues Complete Response Letter for ONS-5010 for Wet AMD

Ophthalmology in 2025: Year in Review

Ophthalmology in 2025: Year in Review

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

6 Ophthalmology Headlines You Missed in October 2025

6 Ophthalmology Headlines You Missed in October 2025

New Parameters for Faster Geographic Atrophy Progression Established, with Srinivas Sadda, MD Srinivas Sadda, MD

The pooled sham cohorts of the OAKS and DERBY trials have revealed a series of indicators for faster geographic atrophy lesion growth.

OCU-410 Gene Therapy Preserves Visual Acuity and Slows GA Lesion Progression, with Jay Chhablani, MD Jay Chhablani, MD

Recent phase 1/2 trial data indicate the safety and efficacy of the surgical, subretinal injection in monitoring cellular homeostasis.

Intravitreal UBX1325 Shows Efficacy in Diabetic Retinopathy, DME, with Dante Pieramici, MD Dante J. Pieramici, MD

Results from the BEHOLD and ASPIRE trials indicate the long lasting effects of UBX1325 in improving retinal function and structure.

Recommended News For You

Effects of Recombinant Replacement Therapy Explained in Detailed Regarding Genetic Clotting Disorder.

Obesity linked to subsequent neoplasms in childhood cancer survivors

Cardiorespiratory fitness lowers the risk of colon, lung, and prostate cancer in MEN and lowers mortality from these diseases.

Clinical trial: Patients with locally advanced, muscle-invasive bladder cancer do not benefit from extended lymph node removal.

Oncology Drug Shortages Persist, but Continue to Evolve

Cancer Diagnoses Slow to Recover From Effects of COVID Pandemic

Study shows virtual reality headsets may help ease cancer pain

Recommended Articles For You

Case Study: Revolutionizing PNH Treatment with Eculizumab for Superior Patient Outcomes 

Priming Agents: A Novel Approach to Enhancing Cell-Free DNA Detection in Liquid Biopsies 

From Bruises to Blood Clots: Everything You Need to Know about Hematoma  

Omega-3 Fatty Acids as Molecular Adjuvants Against Chemoresistance in Breast Cancer 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

An "exploding" field of antibody-drug conjugates is making progress against ovarian cancer.

2.

Telehealth in the pandemic era resulted in fewer therapy interruptions.

3.

Clinical trial is testing whether heavy lifting could combat cancer side effects

4.

In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.

5.

Rural colon cancer patients face higher risks, but minimally invasive surgery could narrow gap

1.

AI Meets the Gut Microbiome: Early Detection of GI Malignancies Redefined

2.

The Growing Crisis of Aplastic Anemia: A Call for Action

3.

Understanding Drug-Induced Cardiotoxicity: Mechanisms, Impact, and Future Directions

4.

Revolutionizing Cancer Treatment: The Promise of Bevacizumab Injections

5.

Unlocking the Potential of Leukemia Treatment: A New Hope for Patients

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

2.

Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World

3.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV

4.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II

5.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot